BR112023014825A2 - Forma mórfica cristalina isolada da forma iii do composto a, forma iii do composto a, composição farmacêutica, forma de dosagem sólida, métodos para tratar coronavírus da síndrome respiratória aguda grave 2 e para tratar vírus da hepatite c, uso da forma iii do composto a ou de uma composição farmacêutica ou forma de dosagem sólida, dispersões sólidas seca por pulverização e em camadas granular, e, fabricação de forma iii do composto a - Google Patents
Forma mórfica cristalina isolada da forma iii do composto a, forma iii do composto a, composição farmacêutica, forma de dosagem sólida, métodos para tratar coronavírus da síndrome respiratória aguda grave 2 e para tratar vírus da hepatite c, uso da forma iii do composto a ou de uma composição farmacêutica ou forma de dosagem sólida, dispersões sólidas seca por pulverização e em camadas granular, e, fabricação de forma iii do composto aInfo
- Publication number
- BR112023014825A2 BR112023014825A2 BR112023014825A BR112023014825A BR112023014825A2 BR 112023014825 A2 BR112023014825 A2 BR 112023014825A2 BR 112023014825 A BR112023014825 A BR 112023014825A BR 112023014825 A BR112023014825 A BR 112023014825A BR 112023014825 A2 BR112023014825 A2 BR 112023014825A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- form iii
- pharmaceutical composition
- solid dosage
- iii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0004—Crystallisation cooling by heat exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Thermal Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163141789P | 2021-01-26 | 2021-01-26 | |
| PCT/US2022/013953 WO2022164941A1 (en) | 2021-01-26 | 2022-01-26 | Advantageous morphic form of at-527 hemi-sulfate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023014825A2 true BR112023014825A2 (pt) | 2023-10-03 |
Family
ID=82653876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023014825A BR112023014825A2 (pt) | 2021-01-26 | 2022-01-26 | Forma mórfica cristalina isolada da forma iii do composto a, forma iii do composto a, composição farmacêutica, forma de dosagem sólida, métodos para tratar coronavírus da síndrome respiratória aguda grave 2 e para tratar vírus da hepatite c, uso da forma iii do composto a ou de uma composição farmacêutica ou forma de dosagem sólida, dispersões sólidas seca por pulverização e em camadas granular, e, fabricação de forma iii do composto a |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230365611A1 (https=) |
| EP (1) | EP4284389A4 (https=) |
| JP (1) | JP2024504392A (https=) |
| KR (1) | KR20230135635A (https=) |
| CN (1) | CN116744939A (https=) |
| AU (1) | AU2022213335A1 (https=) |
| BR (1) | BR112023014825A2 (https=) |
| CA (1) | CA3173656A1 (https=) |
| IL (1) | IL304402A (https=) |
| MX (1) | MX2023008746A (https=) |
| TW (1) | TW202245806A (https=) |
| WO (1) | WO2022164941A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022213335A1 (en) * | 2021-01-26 | 2023-07-27 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Combination anti-HCV therapy is beneficial |
| WO2024211746A1 (en) * | 2023-04-06 | 2024-10-10 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Treatment of autoimmune diseases and cancer with protease inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| US20180214370A1 (en) * | 2017-01-31 | 2018-08-02 | L'oreal | Topcoat for long-wear lip compositions |
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| JP2022510014A (ja) * | 2018-12-05 | 2022-01-25 | アテア ファーマシューティカルズ， インコーポレイテッド | Ｃ型肝炎ウイルスの治療のための高活性な合剤 |
| US10874687B1 (en) * | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022213335A1 (en) * | 2021-01-26 | 2023-07-27 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
-
2022
- 2022-01-26 AU AU2022213335A patent/AU2022213335A1/en active Pending
- 2022-01-26 BR BR112023014825A patent/BR112023014825A2/pt unknown
- 2022-01-26 MX MX2023008746A patent/MX2023008746A/es unknown
- 2022-01-26 CN CN202280011806.3A patent/CN116744939A/zh active Pending
- 2022-01-26 WO PCT/US2022/013953 patent/WO2022164941A1/en not_active Ceased
- 2022-01-26 EP EP22746553.1A patent/EP4284389A4/en active Pending
- 2022-01-26 TW TW111103408A patent/TW202245806A/zh unknown
- 2022-01-26 KR KR1020237028660A patent/KR20230135635A/ko active Pending
- 2022-01-26 JP JP2023544450A patent/JP2024504392A/ja active Pending
- 2022-01-26 CA CA3173656A patent/CA3173656A1/en active Pending
-
2023
- 2023-07-11 IL IL304402A patent/IL304402A/en unknown
- 2023-07-25 US US18/226,064 patent/US20230365611A1/en active Pending
-
2025
- 2025-10-06 US US19/350,713 patent/US20260035404A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230135635A (ko) | 2023-09-25 |
| JP2024504392A (ja) | 2024-01-31 |
| US20230365611A1 (en) | 2023-11-16 |
| TW202245806A (zh) | 2022-12-01 |
| EP4284389A4 (en) | 2025-04-16 |
| EP4284389A1 (en) | 2023-12-06 |
| AU2022213335A1 (en) | 2023-07-27 |
| WO2022164941A1 (en) | 2022-08-04 |
| MX2023008746A (es) | 2023-08-01 |
| CN116744939A (zh) | 2023-09-12 |
| US20260035404A1 (en) | 2026-02-05 |
| IL304402A (en) | 2023-09-01 |
| CA3173656A1 (en) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023014825A2 (pt) | Forma mórfica cristalina isolada da forma iii do composto a, forma iii do composto a, composição farmacêutica, forma de dosagem sólida, métodos para tratar coronavírus da síndrome respiratória aguda grave 2 e para tratar vírus da hepatite c, uso da forma iii do composto a ou de uma composição farmacêutica ou forma de dosagem sólida, dispersões sólidas seca por pulverização e em camadas granular, e, fabricação de forma iii do composto a | |
| JOP20230304A1 (ar) | نظائر تريازولو-بيريميدين لعلاج الأمراض المرتبطة بتثبيط متلازمة Werner RecQ هيليكاز (WRN) | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| UY35962A (es) | Formulaciones de liberación modificada de pridopidina | |
| IL292465B2 (en) | Neuroactive compounds and methods of use thereof | |
| JP2009543798A5 (https=) | ||
| BR112014026643A2 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta | |
| JP2015517488A5 (https=) | ||
| BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| PA8744101A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| BRPI0408486A (pt) | derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
| BR112017023076A2 (pt) | derivados do ácido ciclopropanocarboxílico e seus usos farmacêuticos | |
| EA201892818A1 (ru) | Бета-шпилечные пептидомиметики, обладающие ингибирующей активностью в отношении эластазы, и содержащие их лекарственные формы в виде аэрозоля | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição |